5:56 PM
 | 
May 15, 2013
 |  BC Extra  |  Clinical News

Genentech reports Phase I data for MPDL3280A

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said IV MPDL3280A once every three weeks led to an objective response rate (ORR) of 21% in 140 patients with locally advanced or metastatic solid tumors whose disease had progressed despite prior therapy in an...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >